News

CNTX-4975 is a non-opioid therapy, which is designed to inject directly into the painful joint. The company has secured funding in the series D financing round led by New

With this financing, Temasek joins new and existing investors including 5AM Ventures, Arboretum Ventures, JAZZ Venture Partners, Novartis, Singapore-based EDBI, and the Bridge Builder’s Collaborative. PEAR is the

The consideration is INR 2,800 million (SEK 351 million1) on a cash and debt free basis whereof INR 600 million (SEK 75 million1) will be paid in newly

Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, a marker of classical Hodgkin lymphoma. The FDA is likely to take a call on Adcetris approval by

The Company plans to initiate these studies imminently. Tabelecleucel is Atara's off-the-shelf T-cell immunotherapy in development for the treatment of EBV+PTLD, as well as other EBV associated hematologic

The data from the study demonstrated that the three-part drug has improved certain aspects of memory and thinking ability, as well as helped in limited brain changes associated

Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in the treatment

Atacand is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure.

The transaction amount includes Sucampo’s debt of $360m assumed by the UK-based Mallinckrodt. Amitiza (lubiprostone) has the approvals of the US Food and Drug Administration (FDA) for three